EGFR and hepatocellular carcinoma: In summary, targeting the EGFR/PI3K/AKT/mTOR signaling pathway via the inhibition of EGFR, PI3K, AKT, and/or mTOR has consistently shown anti-tumor effects on HCC cells in vitro (Table 1).